Definition Verastem Oncology is a biopharmaceutical company focused on the development and commercialization of therapies targeting cancer stem cells for the treatment of rare and aggressive cancers.
Overview Verastem Oncology, Inc. is a U.S.-based public biotechnology company headquartered in Needham, Massachusetts. The company was founded in 2010 and is listed on the NASDAQ stock exchange under the ticker symbol VSTM. Its primary research and development efforts are directed toward novel therapeutics designed to target cancer stem cells, which are believed to play a critical role in tumor initiation, metastasis, and resistance to conventional cancer treatments. One of its key investigational agents is defactinib, a focal adhesion kinase (FAK) inhibitor, which has been evaluated in clinical trials for various solid tumor types.
The company has primarily concentrated on developing treatments for rare cancers, including mesothelioma and ovarian cancer, with an emphasis on indications that may qualify for orphan drug designation and accelerated regulatory pathways. Verastem has engaged in clinical collaborations and partnerships with academic institutions and healthcare organizations to advance its oncology pipeline.
Etymology/Origin The name "Verastem" is a compound neologism. It is derived from the Latin root "vera," meaning "true," and "stem," referring to stem cells. This reflects the company's scientific focus on targeting cancer stem cells as a foundational approach to cancer treatment.
Characteristics
- Focus Area: Development of targeted therapies against cancer stem cells.
- Lead Candidates: Defactinib (a FAK inhibitor) and other pipeline molecules in various stages of clinical development.
- Regulatory Designations: The company has received several orphan drug designations from the U.S. Food and Drug Administration (FDA) for its investigational treatments.
- Business Model: Research-driven biopharmaceutical development with reliance on clinical trials, strategic partnerships, and regulatory incentives for rare disease therapies.
- Public Status: Verastem Oncology is a publicly traded company (NASDAQ: VSTM), subject to financial and operational disclosures.
Related Topics
- Cancer stem cells
- Focal adhesion kinase (FAK) inhibitors
- Orphan drug designation
- Targeted cancer therapies
- Mesothelioma
- Ovarian cancer
- Biopharmaceutical industry
- NASDAQ-listed companies